Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

OBJECTIVES: To assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, versus placebo (PBO) in patients with prior inadequate response to tumour necrosis factor inhibitors (TNFi-IRs). METHODS: In this 24-week multicentre, placebo-controlle...

Descripción completa

Detalles Bibliográficos
Autores principales: Feist, Eugen, Fatenejad, Saeed, Grishin, Sergey, Korneva, Elena, Luggen, Michael E, Nasonov, Evgeniy, Samsonov, Mikhail, Smolen, Josef S, Fleischmann, Roy M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664111/
https://www.ncbi.nlm.nih.gov/pubmed/36109142
http://dx.doi.org/10.1136/ard-2022-222630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664111/
https://www.ncbi.nlm.nih.gov/pubmed/36109142
http://dx.doi.org/10.1136/ard-2022-222630

Ejemplares similares